|
J Biol Chem, Vol. 274, Issue 49, 34795-34802, December 3, 1999
3-Adrenergic Stimulation Differentially Inhibits
Insulin Signaling and Decreases Insulin-induced Glucose Uptake in Brown
Adipocytes*
Johannes
Klein §¶,
Mathias
Fasshauer § ,
Moriko
Ito**,
Bradford B.
Lowell**,
Manuel
Benito , and
C. Ronald
Kahn §§
From the Research Division Joslin Diabetes Center and
Department of Medicine, Harvard Medical School, the ** Department of
Medicine, Beth Israel Deaconess Medical Center and Harvard Medical
School, Boston, Massachusetts 02215, and the
 Facultad de Farmacia, Universidad
Complutense, 28040 Madrid, Spain
 |
ABSTRACT |
Activity of the sympathetic nervous system is an
important factor involved in the pathogenesis of insulin resistance and
associated metabolic and vascular abnormalities. In this study, we
investigate the molecular basis of cross-talk between
3-adrenergic and insulin signaling systems in
mouse brown adipocytes immortalized by SV40 T infection.
Insulin-induced tyrosine phosphorylation of the insulin receptor,
insulin receptor substrate 1 (IRS-1), and IRS-2 was reduced by
prestimulation of 3-adrenergic receptors (CL316243). Similarly, insulin-induced IRS-1-associated and
phosphotyrosine-associated phosphatidylinositol 3-kinase (PI 3-kinase)
activity, but not IRS-2-associated PI 3-kinase activity, was reduced by
3-adrenergic prestimulation. Furthermore,
insulin-stimulated activation of Akt, but not mitogen-activated protein
kinase, was diminished. Insulin-induced glucose uptake was completely
inhibited by 3-adrenergic prestimulation. These effects
appear to be protein kinase A-dependent. Furthermore
inhibition of protein kinase C restored the
3-receptor-mediated reductions in insulin-induced IRS-1
tyrosine phosphorylation and IRS-1-associated PI 3-kinase activity.
Together, these findings indicate cross-talk between adrenergic and
insulin signaling pathways. This interaction is protein kinase
A-dependent and, at least in part, protein kinase
C-dependent, and could play an important role in the
pathogenesis of insulin resistance associated with sympathetic
overactivity and regulation of brown fat metabolism.
 |
INTRODUCTION |
The sympathetic nervous system has long been recognized to play an
important role in the pathogenesis of insulin resistance and associated
metabolic and vascular abnormalities, such as type 2 diabetes, obesity,
dyslipidemia, and hypertension (for a recent review see Ref. 1). At a
molecular level, insulin has been shown to phosphorylate tyrosyl
residues in the C terminus of the 2-adrenergic receptor
(2), whereas -adrenergic stimulation can inhibit the activation of
the insulin receptor in some tissues (3-7). However, the potential
molecular mechanisms downstream of these interactions and their effects
remain poorly elucidated.
To investigate the cross-talk between the insulin and adrenergic
signaling systems, we have utilized brown adipocytes. These provide an
attractive cell model for several reasons. Brown adipose tissue
(BAT)1 is highly
regulated by the sympathetic nervous system and expresses different
subtypes of adrenergic receptors (8-10), including the 3-adrenergic receptor, a potential target for
anti-obesity and anti-diabetic drug therapy (11, 12). BAT is important
in controlling energy balance in rodents by its capacity to uncouple
mitochondrial respiration, a process mediated by the expression of the
uncoupling protein-1 (UCP-1) (for recent review see Ref. 13 and
references therein). And finally, BAT is an insulin-sensitive tissue
and contains the main elements of the insulin signaling system
(14-17). Thus, in the cells binding of insulin to its receptor leads
to activation of the receptor kinase and tyrosine phosphorylation of
several insulin receptor substrates (IRS) including IRS-1 and IRS-2.
These, in turn, interact with Src homology 2 (SH2) domain-containing proteins such as phosphatidylinositol 3-kinase (PI 3-kinase), Grb2,
SHP2, and others. Activation of PI 3-kinase leads to activation of the
main downstream effector Akt and stimulation of glucose uptake,
glycogen synthesis, and protein synthesis. Association of IRS proteins
with Grb2 leads to recruitment of SOS and RAS and results in activation
of the MAP kinase pathway, a major regulatory pathway for gene
expression (for recent reviews see Refs. 18-21).
In this study, we present a cell model of immortalized brown adipocytes
and demonstrate molecular evidence for divergent
3-adrenoreceptor-mediated alterations at multiple levels
of the insulin signaling system, including glucose uptake as a final
biological end point.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Fetal bovine serum (FBS) was purchased from
Sigma, bovine serum albumin (BSA) from Arnel Products Co., Inc. (New
York), adenosine deaminase and collagenase from Roche Molecular
Biochemicals, phosphoinositol from Avanti Polar Lipids (Alabaster, AL),
thin layer chromatography plates from VWR (Bridgeport, NJ),
nitrocellulose from Schleicher & Schuell, membranes for Northern
blotting from Micron Separations, Inc. (Westborough, MA), and
electrophoresis supplies from Bio-Rad.
The 3-receptor agonist CL316243 was kindly provided by
Dr. Kurt Steiner (Wyeth Ayerst Research, Princeton, NJ). Antibodies used for immunoprecipitation and immunoblotting included the following: anti-UCP-1 (Alpha Diagnostic International, San Antonio, TX), anti-IRS-1 (raised in rabbit against C terminus), anti-IRS-2 (raised in
rabbit against PH domain and C terminus), antiphosphotyrosine 4G10
(kindly provided by Dr. Morris White, Joslin Diabetes Center, Boston,
MA), anti-insulin receptor (kindly provided by Dr. Bentley Cheatham,
Joslin Diabetes Center, Boston, MA), polyclonal anti-PI 3-kinase p85
(Upstate Biotechnology, Inc., Lake Placid, NY), antiphosphospecific MAP
kinase, antiphosphospecific Akt (New England Biolabs, Beverly, MA), and
anti-Akt (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Protein
A-Sepharose was from Amersham Pharmacia Biotech, and the PKC assay
system was from Promega (Madison, WI). Penicillin/streptomycin and the
PKA assay system were from Life Technologies, Inc.; forskolin, the PKC
inhibitors GF109203X and Ro-31-8245 were from Calbiochem; 2-deoxy-[3H]glucose and [ -32P]ATP were
from NEN Life Science Products, and 125I-protein A was
supplied by ICN Biochemicals, Inc. (Costa Mesa, CA). All other supplies
were from Sigma.
Cell Isolation and Culture--
Interscapular brown adipose
tissue was isolated from newborn FVB mice (Taconic), minced, and
subjected to collagenase digestion (2 mg of collagenase in 2 ml of
isolation buffer containing 0.123 M NaCl, 5 mM
KCl, 1.3 mM CaCl2, 5 mM glucose,
100 mM Hepes, and 4% BSA) for 30 min. The digested tissue
was filtered through a 100-µm nylon screen. Collected cells were
centrifuged (200 × g) for 5 min. The pellet consisting
of precursor cells was washed once in isolation buffer and centrifuged
again. Cells were resuspended in 2 ml of culture medium (Dulbecco's
modified Eagle medium (DMEM) containing 25 mM glucose, 20%
FBS, 20 mM Hepes, 100 units/ml penicillin/streptomycin), seeded on two 35-mm plates, and grown in a humidified atmosphere of 5%
CO2 and 95% air. The medium was changed every day. After reaching 80% confluence, cells were passed to 10-cm plates and infected with the puromycin resistance retroviral vector pBabe encoding
SV40 T antigen (kindly provided by Dr. J. DeCaprio, Dana Farber Cancer
Institute, Boston) for 24 h. Following infection, the brown
adipose precursor cells were maintained in culture medium for 72 h
and then subjected to selection with puromycin (1 µg/ml) for at least
3 weeks.
For differentiation, selected preadipocytes were grown to confluence in
culture medium supplemented with 20 nM insulin and 1 nM T3 (differentiation medium). Confluent cells were
incubated for 24 h in differentiation medium further supplemented
with 0.5 mM isobutylmethylxanthine, 0.5 µM
dexamethasone, and 0.125 mM indomethacin (induction
medium). Subsequently, the cells were maintained in differentiation
medium for 4-5 days until exhibiting a fully differentiated
phenotype with massive accumulation of multilocular fat droplets.
Experiments were carried out after starving the cells in serum-free
medium for 16-18 h. Unless indicated otherwise, cells were pretreated
for 30 min with adenosine deaminase (2 units/ml), followed by the
3-adrenergic agent for 30 min, and then stimulated with
insulin for 5 min. All experiments were performed within 20 passages following immortalization.
Immunoprecipitation and Western Blot Analysis--
At the end of
the stimulation period, cells were washed twice with ice-cold PBS and
lysed in extraction buffer (50 mM Hepes, 137 mM
NaCl, 1 mM MgCl2, 1 mM
CaCl2, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 2 mM EDTA, 10% glycerol,
1% Igepal CA-630, 2 mM vanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride, pH
7.4). Cell lysates were clarified by centrifugation at 12,000 × g for 10 min at 4 °C. The fat cake was removed with cotton-tipped applicators, and the supernatants were transferred to
fresh tubes. Protein amount was determined by the Bradford method (22)
using BSA as standard, and the dye reagent concentrate was from
Bio-Rad. Equal amounts of protein (100 µg and 1 mg, respectively) were either directly solubilized in Laemmli sample buffer (LSB) or
immunoprecipitated for at least 2 h at 4 °C with the indicated antibodies. Immune complexes were collected by adding 50 µl of a 50%
slurry of protein A-Sepharose in phosphate-buffered saline (PBS) for
1 h at 4 °C. After three washes in extraction buffer immunoprecipitates were solubilized in LSB. Lysates or
immunoprecipitates were boiled for 2 min, separated by SDS-PAGE, and
transferred to nitrocellulose membranes. Membranes were blocked in TBS
(10 mM Tris, 0.15 mM NaCl, 0.05% Tween, pH
7.2) containing 3% BSA for 30 min, incubated with the respective
antibodies for 2 h, washed 3 times for 5 min each in TBS, and
incubated with 125I-protein A for 45 min. After three
washes for 5 min each, the immunoblots were exposed on a PhosphorImager
screen, and signals were quantified using a Molecular Dynamics densitometer.
PI 3-Kinase Assays--
Cells were incubated with or without the
indicated hormones in non-serum-containing DMEM with 25 mM
glucose for the indicated periods, and lysates were obtained as
described above. Supernatants containing 1 mg of protein were
immunoprecipitated for 2 h at 4 °C with the appropriate
antibodies, and the immune complexes were collected by adding 50 µl
of a 50% slurry of protein A-Sepharose in PBS for 1 h at 4 °C.
The immune complexes were washed twice with PBS containing 1%
Igepal-CA 630, twice with 0.5 M LiCl, 0.1 M
Tris, pH 7.5, and twice in reaction buffer (10 mM Tris, pH
7.5, 100 mM NaCl, 1 mM EDTA). Sepharose beads
were resuspended in a mixture containing 50 µl of reaction buffer, 10 µl of 100 mM MgCl2, and 10 µl of
phosphatidylinositol (2 µg/µl, previously dried under a gentle
argon stream and resuspended in 10 µl of 10 mM Tris, pH
7.5, 1 mM EGTA by sonication at 4 °C). Reactions were
initiated by addition of 5 µl of a solution containing 880 µM ATP, 20 mM MgCl2, and 10 µCi
of [ 32P]ATP (3.000 Ci/mmol) per tube. The reactions
were stopped after 10 min by adding 20 µl of 8 N HCl and
160 µl of CHCl3/methanol (1:1). After a brief
centrifugation in a desktop centrifuge, 50 µl of the lower organic
phase of each sample were spotted on a silica gel thin layer
chromatography plate. The plate was developed in
CHCl3/methanol/H2O/NH4OH
(120:94:23:2.4), dried, exposed to a PhosphorImager screen, and
quantitated with a Molecular Dynamics densitometer.
Protein Kinase Assays--
Protein kinase B/Akt assays were
performed essentially as described (23). Briefly, immunoprecipitates
with anti-Akt antibody were washed and resuspended in 40 µl of
reaction buffer (50 mM Tris, pH 7.5, 10 mM
MgCl2, 1 mM dithiothreitol, 40 µM
ATP, 3 µCi of [ -32P]ATP, 5 µg Crosstide). After 20 min at 30 °C the reaction was stopped, and aliquots were spotted on
squares of P-81 paper, washed, and counted by Cerenkov. Protein kinase
A and C assays were done according to the manufacturer's instructions.
Northern Blot Analysis--
Northern blot analysis was performed
according to standard techniques using denaturing
formaldehyde-containing agarose gels (24). After stimulation with the
indicated reagents for 4 h, total cellular RNA was isolated by
using RNA Stat-60 (Tel-Test "B", Inc., Friendswood, TX). 20 µg of
RNA was subjected to electrophoresis in 1.2% agarose gels. Ethidium
bromide staining of the gels confirmed equal loading and integrity of
the RNA. RNA was transferred to nylon membranes (Micron Separations,
Inc., Westborough, MA), and blots were hybridized with 25 ng of a
UCP-1-specific cDNA probe previously labeled by using a random
prime labeling kit (Promega, Co., Madison, WI) for 2 h at
65 °C. Blots were washed once in 2× SSC, 0.1% SDS at room
temperature for 20 min and once in 0.1× SSC, 0.1% SDS at 65 °C for
20 min. Membranes were allowed to air-dry and exposed on a
PhosphorImager Screen followed by quantitation with a Molecular
Dynamics densitometer.
Glucose Uptake Assays--
Cells were assayed for glucose uptake
essentially as described (25). Differentiated monolayers of brown
adipocytes were pretreated with 2 units/ml adenosine deaminase for 30 min. Unless indicated otherwise, subsequent pretreatment with the
3-selective agonist CL316243 was for 30 min, before
insulin was added for another 30 min. At the end of the stimulation
period, cells were exposed to 50 µl of
2-deoxy-[3H]glucose (0.5 µCi/ml final concentration)
for 3 min. The incorporated radioactivity was determined by liquid
scintillation counting of triplicate points.
Statistical Analysis--
Results are indicated as mean ± S.E. for all data. Unpaired Student's t tests were used for
analysis of differences between various cell treatments. p
values <0.05 are considered significant and <0.01 highly significant.
 |
RESULTS |
Immortalized Preadipocytes Can Be Differentiated into Mature Brown
Adipocytes--
Brown fat precursor cells were isolated from
interscapular brown fat of newborn mice and immortalized by SV40 T
antigen infection as described under "Experimental Procedures."
Preadipocytes showed a spindle-shaped morphology similar to fibroblasts
(Fig. 1A, top panel, left).
Northern blot analysis revealed no detectable UCP-1 mRNA in brown
fat precursor cells (data not shown), and no fat accumulation could be
seen using the fat-specific Oil Red O staining (Fig. 1A, bottom
panel, left). Following differentiation with insulin, T3,
indomethacin, isobutylmethylxanthine, and dexamethasone, confluent
cells became smaller, rounded up, accumulated fat, and the
cytoplasm/nucleus-ratio increased dramatically. Once fully differentiated, multilocular fat droplets could be detected both microscopically (Fig. 1A, top panel, right) and by Oil Red O
staining (Fig. 1A, bottom panel, right). UCP-1 mRNA was
expressed in the basal state and could be further increased by
3-4-fold upon 3-receptor-specific (CL316243)
stimulation (Fig. 1C). This was paralleled by changes in
UCP-1 at the protein level (Fig. 1D). An important
functional characteristic of adipocytes, including brown adipocytes, is
insulin-dependent glucose uptake. Insulin-induced glucose
uptake in our cell lines was dose-responsive with a submaximal,
approximately 6-fold increase at an insulin concentration of 10 nM (Fig. 1B). For cross-talk experiments, we
used a maximally stimulatory concentration of insulin of 100 nM, unless indicated otherwise.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 1.
Brown adipocyte cell model. Brown
adipose tissue precursor cells were isolated from newborn mice as
described under "Experimental Procedures." A, after
selection with puromycin (1 µg/ml) for 3 weeks, SV40 T-immortalized
cells were maintained in DMEM containing 25 mM glucose and
20% FBS. When the cells reached confluence, differentiation was
induced with dexamethasone, indomethacin, and isobutylmethylxanthine. 5 days later massive accumulation of multilocular fat droplets in
differentiated adipocytes is demonstrated microscopically (× 40 magnification, hematoxylin-stained) and by Oil Red O staining.
B, cells were differentiated in 12-well plates, starved for
48 h in DMEM containing 25 mM glucose, and
subsequently assayed for glucose uptake in triplicate at the indicated
insulin concentrations. C, differentiated brown adipocytes
were stimulated for four hours with the
3-receptor-specific agonist CL316243 (100 µM). UCP-1 mRNA of non-stimulated and stimulated
cells was detected by Northern blotting using a
-32P-labeled UCP-1-specific cDNA. D,
differentiated brown adipocytes were treated with 10 µM
CL316243 for 18 h. UCP-1 protein in cell lysates was visualized by
immunoblotting with a UCP-1-specific antibody and
125I-labeled protein A.
|
|
Insulin-induced Tyrosine Phosphorylation of the Insulin Receptor,
IRS-1, and IRS-2 Is Reduced by 3-Adrenergic
Pretreatment--
To investigate the molecular basis of an interaction
between adrenergic and insulin signaling systems, we first assessed
changes at proximal steps of the insulin signaling cascade. Insulin
alone produced an approximately 10-fold increase in tyrosine
autophosphorylation of the -subunit of its receptor in
differentiated brown adipocytes. This was diminished by 40% in
3-receptor agonist (CL316243)-pretreated brown
adipocytes as compared with insulin treatment alone (Fig. 2A), a statistically highly
significant reduction. Insulin-induced IRS-1 tyrosine phosphorylation
was reduced in parallel by 45% when cells were pretreated with the
CL316243 as compared with insulin treatment alone (Fig. 2B).
By contrast, the decrease in insulin-induced tyrosine phosphorylation
of IRS-2 was reproducibly less and averaged only 28% under the same
treatment conditions (Fig. 2C). These alterations in
insulin-mediated IRS-1 and IRS-2 tyrosine phosphorylation were highly
statistically significant. Treatment with the
3-adrenoreceptor agonist alone had no significant effect
on the basal tyrosine phosphorylation neither of the insulin receptor
nor of IRS-1 or IRS-2.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Insulin-induced tyrosine phosphorylation of
the insulin receptor, IRS-1 and IRS-2, is reduced by
3-adrenergic prestimulation. Brown
adipocytes were starved in serum-free medium (DMEM containing 25 mM glucose) for 18 h, pretreated with adenosine
deaminase (2 units/ml) for 30 min, and stimulated with insulin
(Ins, 100 nM) for 5 min, either with or without
prior treatment for 30 min with the 3-receptor-specific
agonist CL316243 (Cl- 3, 100 nM). Protein
lysates were subjected to immunoprecipitation with antibodies against
the insulin receptor -subunit, IRS-1, and IRS-2, respectively,
followed by SDS-PAGE and Western blotting using a
phosphotyrosine-specific antibody. A representative experiment and the
statistical analysis of at least six independent experiments with the
S.E. are shown. ** denotes p < 0.01 comparing insulin
stimulation alone with insulin treatment after 3-agonist
pretreatment.
|
|
3-Adrenergic Prestimulation Reduces Insulin-induced
p85 Binding to IRS-1 but Not IRS-2--
A pivotal regulator for most
of the metabolic actions of insulin is activation of the lipid kinase
PI 3-kinase. This occurs by binding of the p85 regulatory subunit of PI
3-kinase to tyrosine-phosphorylated insulin receptor substrates such as
IRS-1 and IRS-2 with subsequent activation of the p110 catalytic
subunit of the enzyme. By immunoprecipitating cell lysates with
IRS-specific antibodies and immunoblotting with an antibody detecting
the p85-subunit, we found that insulin treatment alone induced a 4-fold
increase in p85 binding to IRS-1 as compared with the basal state.
Activation of the 3-adrenergic receptor prior to insulin
stimulation reduced the insulin-induced increase in p85 binding to
IRS-1 by 45%. This alteration was highly statistically significant
(Fig. 3A, top panel). The
association of IRS-2 with p85 was also increased 3-fold upon insulin
treatment alone. However, in contrast to the changes seen with IRS-1,
pretreatment with the 3-adrenoreceptor agonist resulted
in only a 15% decrease in p85 binding to IRS-2, and this change did
not reach the level of statistical significance (Fig. 3B, top
panel). Thus, 3-adrenergic stimulation reduced
insulin receptor phosphorylation, IRS-1 phosphorylation, and p85
binding to IRS-1 about 40-45% but had a much smaller effect on IRS-2
phosphorylation and no significant effect on p85 docking to IRS-2.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
Insulin-induced p85 binding to IRS-1 and
IRS-1-associated PI 3-kinase activity are reduced by
3-adrenergic stimulation but not IRS-2
p85 binding and IRS-2-associated PI 3-kinase activity. After
starving cells for 18 h in serum-free medium (DMEM containing 25 mM glucose), adipocytes were pretreated with adenosine
deaminase (2 units/ml) for 30 min and then stimulated for 5 min with
insulin (Ins, 100 nM), with or without prior
3-adrenergic stimulation (Cl- 3, 100 nM) for 30 min. Protein lysates were subjected to
immunoprecipitation with antibodies against IRS-1 (A) or
IRS-2 (B), respectively, followed by SDS-PAGE and Western
blotting using an anti-PI 3-kinase p85 antibody. PI 3-kinase activities
in immunoprecipitates were measured in duplicate as described under
"Experimental Procedures." A representative experiment and the
statistical analysis with the S.E. of at least three independent
experiments are shown. ** denotes p < 0.01 comparing
insulin stimulation alone with insulin treatment after
3-agonist pretreatment.
|
|
Insulin-induced IRS-1- but Not IRS-2-associated PI 3-Kinase
Activity Is Decreased after 3-Agonist
Pretreatment--
To determine the effects of these changes in p85
subunit binding, we performed in vitro PI 3-kinase assays on
IRS-1- and IRS-2-associated PI 3-kinase, as described under
"Experimental Procedures." IRS-1-associated PI 3-kinase activity
was strongly increased upon insulin treatment. 3-Agonist
pretreatment prior to insulin stimulation led to a 40% decrease in
activity as compared with insulin treatment alone (Fig. 3A,
bottom panel). This change was statistically highly significant
and paralleled the reduction in p85 binding. IRS-2-associated PI
3-kinase activity was also strongly induced by insulin. However, pretreatment with the 3-receptor agonist did not result
in a significant change of insulin-induced PI 3-kinase activity
consistent with the lack of effect on p85 binding to this insulin
receptor substrate (Fig. 3B, bottom panel).
3-Receptor Agonist Pretreatment Diminishes
Insulin-stimulated Phosphotyrosine-associated PI 3-Kinase Activity and
Activation of Akt but Not MAP Kinase--
As a parameter for the total
insulin-induced PI 3-kinase activity, we performed PI 3-kinase activity
assays in phosphotyrosine immunoprecipitates. Again, insulin treatment
alone induced a strong increase in PI 3-kinase activity.
3-Adrenergic prestimulation reduced this increase by
30% (p < 0.01) (Fig.
4A).
3-Adrenergic stimulation alone also significantly
reduced the basal activity level, an effect less appreciated with the
individual substrates (Fig. 4A).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Insulin-stimulated phosphotyrosine-associated
PI 3-kinase activity as well as Akt phosphorylation and activation but
not phosphorylation of MAP kinase are reduced by
3-adrenoreceptor agonist
treatment. Brown adipocytes, serum-starved for 18 h and
pretreated with adenosine deaminase (2 units/ml) for 30 min, were
treated for 5 min with insulin (Ins, 100 nM)
following 3-adrenergic prestimulation
(Cl- 3, 100 nM) for 30 min where indicated.
A, PI 3-kinase activities in immunoprecipitates were
measured in duplicates as described under "Experimental
Procedures." B and C, Western blot analysis
using phospho-specific antibodies detecting the active forms of Akt and
the p42/p44 isoforms of MAP kinase. D, Akt kinase activity
was measured as described under "Experimental Procedures." The
statistical analysis with S.E. for at least six independent experiments
is depicted in the bar graphs. *, p < 0.05;
**, p < 0.01; pY, phosphotyrosine.
|
|
PI 3-kinase mediates the activation of Akt, and this has been closely
linked to glucose transport. By immunoblotting with a phospho-specific
antibody to activated Akt, we found a 10-fold increase in
phosphorylation of this enzyme over basal levels by insulin stimulation
alone. Following 3-adrenergic prestimulation, the
insulin-mediated Akt phosphorylation was reduced by 25%
(p < 0.01) (Fig. 4B). This decrease was
accompanied by a 15% reduction in Akt kinase activity
(p < 0.01) (Fig. 4D). Phosphorylation of MAP kinase, another key regulator in insulin and growth factor signaling pathways, was also increased 5-fold by insulin stimulation alone, as determined by immunoblots using a phospho-specific antibody against the activated isoforms p42 and p44. Stimulation with the 3-adrenoreceptor agonist CL316243 alone also led to a
small but significant increase in MAP kinase phosphorylation over the
basal state. However, 3-adrenergic prestimulation did
not further augment the insulin-mediated increase but tended to rather
decrease it, although this change was not significant
(p = 0.15) (Fig. 4C).
3-Adrenoreceptor-mediated Alterations of Insulin
Signaling Components Are PKA-dependent--
G subunits
of -adrenergic receptors activate membrane-bound adenylyl cyclase
thereby increasing intracellular cAMP-levels which, in turn, activate
protein kinase A (PKA). Indeed, pretreatment of brown adipocytes with
dibutyryl cAMP and the adenylyl cyclase-activating compound forskolin
could mimic the molecular changes observed with
3-adrenergic pretreatment (Fig.
5). Insulin-induced IRS-1 phosphorylation
(Fig. 5A), p85 binding to IRS-1 (Fig. 5B), and IRS-1-associated PI 3-kinase activity (Fig. 5C) as well as
insulin receptor, IRS-2, and Akt phosphorylation (data not shown) were decreased significantly after pretreating brown adipocytes with these compounds. Additionally, pretreatment of these cells with the
specific PKA inhibitor H-89 could reverse the IRS-1-associated effects
observed after CL316243 treatment (Fig. 5, A-C), as well as
the changes in insulin receptor, IRS-2, and Akt phosphorylation (data
not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
The
3-adrenergic inhibitory effect on
insulin-induced IRS-1 tyrosine phosphorylation, IRS-1 p85 binding, and
IRS-1-associated PI 3-kinase activity is
PKA-dependent. After 18 h starvation, cells were
pretreated with adenosine deaminase (2 units/ml) for 30 min and then
incubated with the compounds indicated. Pretreatment with H-89 (10 µM) was for 1 h, with forskolin (50 µM), dibutyryl cAMP (DB-cAMP, 1.5 mM) and CL316243 (Cl- 3, 100 nM)
for 30 min. Where indicated adipocytes were treated with insulin (100 nM) for 5 min at the end of this incubation period. Protein
lysates were subjected to immunoprecipitation with an
anti-IRS-1-specific antibody and blotted using an anti-phosphotyrosine
antibody (A) and an anti-PI 3-kinase p85 antibody
(B), respectively. PI 3-kinase assays in IRS-1
immunoprecipitates were performed (C) as described under
"Experimental Procedures." A representative experiment is shown
together with the statistical bar graph analysis with the S.E. of at
least three independent experiments. *, p < 0.05; **
p < 0.01.
|
|
Inhibition of PKC Restores the
3-Adrenoreceptor-mediated Decrease in Insulin-induced
IRS-1 Tyrosine Phosphorylation, IRS-1 p85 Binding, and IRS-1-associated
PI 3-Kinase Activity but Leaves IRS-2 Alterations Unaffected--
G
subunits of G protein-coupled receptors have been shown to activate PKC
isoforms. To determine whether PKC might play a role in the signaling
pathways responsible for the alterations observed, the influence of
general PKC inhibition on the effects of -adrenergic agents was
studied using the general PKC inhibitors GF109203X and Ro-31-8425. The
decrease in insulin-induced tyrosine phosphorylation of IRS-1 caused by
3-adrenergic prestimulation was restored by inhibition
of PKC (Fig. 6A). Furthermore,
the 3-adrenoreceptor-mediated reductions in
insulin-induced IRS-1 binding to the p85 subunit of PI 3-kinase and
IRS-1-associated PI 3-kinase activity also were rescued by PKC
inhibition (Fig. 6, B and C). PKC inhibition
alone or in combination with insulin did not have significant effects
on the basal or the insulin-stimulated levels of phosphorylation or p85
binding and associated PI 3-kinase activity (data not shown). The
rescuing effect of PKC inhibition was specific for IRS-1. Inhibition of
PKC did not result in significant changes in insulin-induced tyrosine
phosphorylation of the receptor -subunit, IRS-2 tyrosine
phosphorylation, p85 binding, or IRS-2-associated PI 3-kinase activity
after CL316243 treatment (data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of PKC restores the
3-adrenergic inhibitory effect on
insulin-induced IRS-1 tyrosine phosphorylation, IRS-1 p85 binding, and
IRS-1-associated PI 3-kinase activity. After 18 h starvation,
cells were pretreated with adenosine deaminase (2 units/ml) for 30 min
and then incubated with the compounds indicated (GFX,
general PKC inhibitor GF109203X, 5 µM; Ro,
general PKC inhibitor Ro-31-8425, 10 µM;
Cl- 3, CL316243, 100 nM). Pretreatment with
GF109203X and Ro-31-8425 was for 30 min, followed by the
3-adrenoreceptor agonist for 30 min and insulin (100 nM) for 5 min where indicated. Protein lysates were
subjected to immunoprecipitation with an anti-IRS-1-specific antibody
and blotted using an anti-phosphotyrosine antibody (A) and
an anti-PI 3-kinase p85 antibody (B), respectively. PI
3-kinase assays in IRS-1 immunoprecipitates were performed
(C) as described under "Experimental Procedures." A
representative experiment is shown together with the statistical bar
graph analysis with the S.E. of at least three independent experiments.
*, p < 0.05; **, p < 0.01.
|
|
Insulin-induced Glucose Uptake Is Reduced by
3-Adrenergic Pretreatment--
One of the major effects
of insulin signaling is stimulation of glucose uptake. Insulin alone
induced an approximately 6-fold increase in glucose uptake in these
differentiated culture brown adipocytes. Pretreating cells with the
3-adrenoreceptor agonist CL316243 for only 5 min prior
to insulin treatment reduced the insulin-stimulated glucose uptake by
55%. The inhibition became almost complete after 40 min of treatment
with CL316243 (Fig. 7A). The
inhibitory effect of 3-adrenergic prestimulation on insulin-induced glucose uptake was dose-dependent.
Pretreatment of cells with CL316243 at a concentration of 1 nM reduced the insulin-mediated glucose uptake by 50%, and
insulin-induced glucose uptake was almost completely abolished at a
concentration of 100 nM (Fig. 7B). Treatment
with 100 nM CL316243 alone did not have a significant
effect on the basal level of glucose uptake. The inhibition of
insulin-induced glucose uptake by 3-adrenergic prestimulation could be mimicked with dibutyryl cAMP and forskolin treatment (Fig. 7C). Additionally, the decrease in
insulin-induced glucose uptake after CL316243 pretreatment could be
partially rescued by inhibition of PKA with H-89 (Fig. 7C).
In contrast, the PKC inhibitor GF109203X itself had a negative effect
on insulin-induced glucose uptake and did not rescue glucose uptake
after 3-agonist prestimulation (Fig. 7D).
However, when brown adipocytes were treated overnight with 1 µg/ml
PMA to down-regulate classical ( , , and ) and novel ( , ,
, and ) PKC isoforms, insulin-induced 2-deoxyglucose uptake was
only reduced by 24% after 3-agonist pretreatment in
PMA-treated cells compared with 64% in non-PMA-treated adipocytes
(Fig. 7E).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Insulin-induced glucose uptake is inhibited
by 3-adrenergic stimulation.
Brown adipocytes, serum-starved for 48 h and pretreated with
adenosine deaminase (2 units/ml) for 30 min, were stimulated with
insulin (100 nM) for 30 min. The
3-adrenoreceptor agonist CL316243 (Cl- 3)
was added at the indicated times prior to the insulin treatment at a
concentration of 100 nM (A) or at the indicated
concentrations 30 min prior the insulin treatment (B),
respectively. C, pretreatment with H-89 (10 µM) was for 1 h, with forskolin (50 µM), dibutyryl cAMP (DB-cAMP, 1.5 mM), and CL316243 (Cl- 3, 100 nM)
for 30 min before insulin (100 nM) was added to the medium
for 30 min, as indicated. D, pretreatment with GF109203X was
for 30 min, followed by the 3-adrenoreceptor agonist for
30 min and insulin (100 nM) for 30 min where indicated.
E, brown adipocytes were either non-treated or incubated
overnight with PMA. Cl- 3 (CL316243, 100 nM)
was added for 30 min prior to insulin treatment (100 nM, 30 min), as indicated. 2-Deoxyglucose (2-DOG) uptake is
presented as percentage of the insulin-induced uptake (100%). The
graphs in B-E present the average and the S.E.
of at least three independent experiments. *, a statistically
significant difference (p < 0.05); **, a highly
significant difference (p < 0.01) as compared with
insulin treatment alone (B-E) or CL316243 + insulin
(C).
|
|
 |
DISCUSSION |
By using a brown adipocyte cell model, we have studied the
molecular mechanisms of interaction between sympatho-adrenergic and
insulin signaling pathways and action. We have utilized SV40 T
antigen-immortalized brown adipocytes, since these cells exhibit a
highly differentiated phenotype and can be established from different
animal models of insulin resistance from a single newborn mouse.
Brown fat is a characteristic target tissue for
3-adrenergic agents that regulate adaptive thermogenesis
in these cells by virtue of expression of the mitochondrial protein
UCP-1. These cells also exhibit the classical function of insulin in
fat, i.e. stimulation of glucose transport. Our cell lines
demonstrate both insulin-induced glucose uptake and expression of UCP-1
at mRNA and protein level in the basal state as well as in response
to 3-adrenergic stimulation. As compared with other well
studied white adipose cell lines, e.g. 3T3-L1 cells,
insulin-stimulated glucose uptake in differentiated brown adipocytes is
similarly robust (6-fold stimulation) and sensitive (submaximal
response at 10 nM insulin). Furthermore, these cells
exhibit the typical morphology of mature brown adipocytes with massive
accumulation of multilocular fat.
In this study, we find that 3-adrenergic prestimulation
results in a decrease in insulin-stimulated receptor tyrosine
phosphorylation. This most likely reflects decreased receptor kinase
activity and is consistent with a number of previous studies in rat and
human adipocytes showing a decrease in receptor kinase activity by
nonspecific -adrenergic stimulation with isoproterenol (3-7). The
decrease in receptor tyrosine phosphorylation was not accompanied by a shift in mobility of the receptor -subunit on SDS gels (data not
shown), suggesting that it is not due to increased serine/threonine phosphorylation of the receptor. This finding is in accordance with
studies by Issad et al. (3) who were unable to detect increased serine/threonine phosphorylation of the insulin receptor by
phosphopeptide mapping following adrenergic stimulation.
In parallel with the decrease in receptor tyrosine phosphorylation,
insulin-induced tyrosine phosphorylation of IRS-1, and to a lesser
extent IRS-2, was also reduced by 3-adrenergic
pretreatment. This is due to a decrease in receptor tyrosine kinase
activity as indicated by the diminished receptor tyrosine
phosphorylation. However, this differentially affects IRS-1 and IRS-2.
In this context, it should be noted that the C-terminal regions of
IRS-1 and IRS-2 are rather poorly conserved (35% identity) (21), and the presence of different receptor binding domains such as the "kinase regulatory loop binding domain" which is present in IRS-2, but not IRS-1 (26), might well explain the difference observed. Different compartmentalization and trafficking of IRS-1 and IRS-2 have
been observed in fat cells and might also play a role (27). Furthermore, as IRS-2 is more rapidly phosphorylated than IRS-1 (data
not shown), we cannot exclude the possibility that CL316243-induced changes in p85 binding to IRS-2 and IRS-2-associated PI 3-kinase activity can be observed at different time points of insulin stimulation.
At the level of PI 3-kinase activity, insulin-induced
phosphotyrosine-associated PI 3-kinase activity was decreased by
3-adrenergic prestimulation, both in the basal state and
after insulin stimulation. This suggests insulin receptor-independent
and receptor-dependent cross-talking mechanisms. In
agreement with this work, Ohsaka et al. (28) have
demonstrated that insulin-stimulated PI 3-kinase activity is suppressed
by 3-adrenergic stimulation in rat adipocytes via a
direct cAMP-dependent mechanism. Furthermore, this decrease in PI 3-kinase activity is associated with a reduction in
insulin-induced activation of Akt. It is likely to be caused, at least
in part, by the decreased PI 3-kinase activity observed, but Akt has
also been demonstrated to be regulated by PI 3-kinase-independent
stimuli including stress (29, 30). Thus, again a number of separate signaling pathways is likely to interact at this level.
MAP kinase in brown adipocytes is activated by both insulin and
3-adrenergic stimulation (present study and Ref. 31).
The potential mechanism for this G protein-coupled receptor-mediated MAP kinase activation is under intensive investigation. One possible pathway involves G subunits (reviewed in Ref. 32). Also, evidence has been presented for Gs initiating MAP kinase
activation (33, 34). Interestingly, 3-adrenergic
stimulation prior to insulin treatment did not result in a further
increase of MAP kinase activation but rather tended to decrease it. In
the context of our data, a plausible explanation is that the inhibition
of insulin-induced signaling pathways upstream of MAP kinase might
prevent a sufficient insulin-stimulated increase.
Surprisingly, despite only modest decreases in PI 3-kinase and even
smaller decreases in Akt activation, the inhibition of insulin-induced
glucose uptake by 3-adrenergic prestimulation was almost
complete. From these observations two non-mutually exclusive
conclusions could be drawn. On the one hand, it is possible that a
small decrease in Akt activation as detected on immunoblots and by
in vitro kinase assays might be sufficient to cause a
considerable inhibition of glucose uptake. Alternatively, inhibition of
insulin-induced glucose uptake after 3-agonist treatment
might be mediated by Akt-independent pathways. Recent studies using a
dominant negative Akt mutant lend support to the latter hypothesis
(35).
In our cells, 3-adrenergic stimulation alone did not
result in a significant increase in glucose uptake. This is in contrast to previous reports that demonstrated an approximately 2-fold increase
in glucose uptake in response to (nor)adrenergic stimulation using
cultured rat brown adipocytes (36, 37). We do not know the cause for
this discrepancy. It is conceivable that differences in the
experimental systems such as cell starvation periods, stimulation times, the presence or absence of adenosine in the culture media, and
the usage of different adrenergic compounds at different concentrations are responsible.
Finally, our data suggest both PKA-dependent and
PKC-dependent signaling pathways mediating the
3-adrenergic effects on the insulin signaling system.
Treatment of brown adipocytes with dibutyryl cAMP and forskolin
resulted in significant changes similar to CL316243 treatment, and
inhibition of PKA by H-89 reversed all changes detected after
3-agonist pretreatment. Furthermore, PKC inhibition
rescued the 3-receptor-mediated decreases in
insulin-induced IRS-1 tyrosine phosphorylation, p85 binding, and
IRS-1-associated PI 3-kinase activity. We performed PKA activity assays
to exclude the possibility that this rescuing effect of the PKC
inhibitors could be explained by an additional PKA inhibitory effect of
GF109203X and Ro-31-8425. Whereas the PKA inhibitor H-89 decreased PKA
kinase activity by 75%, no change of this protein kinase was
detectable after PKC inhibitor treatment (data not shown). Whereas
adrenergic activation of PKA has long been known to alter insulin
receptor tyrosine kinase activity (38) in brown adipocytes, at present, the signaling pathway from -adrenergic receptors to activation of
PKC in general and its consequences are poorly understood. PKC has been
shown to be activated by the 2-adrenergic receptor (39).
In Swiss 3T3 fibroblasts, PKC and other unidentified isoforms are
involved in the -adrenergic receptor coupling to adenylate cyclase
(40). However, as we did not see changes in total or isoform-specific
PKC activity after exposure of adipocytes to CL316243 (data not shown),
the detailed mechanisms of activation and the identity of PKC isoforms
involved remain unknown. On the other hand, our observation that
inhibition of PKC decreased the insulin-stimulated glucose uptake also
suggests the involvement of PKC isoforms as positive regulators. This
is consistent with recent studies demonstrating a role for the atypical
PKC isoforms and in mediating this insulin effect (41-43).
In summary, we have characterized the cross-talk between adrenergic and
insulin signaling pathways in a brown adipocyte cell model at different
levels. We find that 3-adrenergic stimulation inhibits
insulin signaling and insulin-induced glucose uptake. The mechanisms
presented here might constitute a molecular basis important in the
pathogenesis of insulin resistance in states of adrenergic overactivity
and in brown adipocyte metabolism.
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Kurt Steiner
(Wyeth-Ayerst Research, CN 8000, Princeton, NJ) for the kind gift
of the 3-adrenoreceptor agonist CL316243. We gratefully
acknowledge Dr. James DeCaprio (Dana Farber Cancer Institute, Boston)
for providing us with the retroviral pBabe vector coding for SV40T. We
are indebted to Pere Puigserver for helpful advice and comments
at many experimental stages of this work and to Terri-Lyn Azar and
Catherine Remillard for excellent secretarial assistance.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants DK 33201 and Joslin's Diabetes and Endocrinology
Research Center Grant DK 36836.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors equally contributed to this work.
¶
Supported by Grant Kl-1131/1 from the Deutsche Forschungsgemeinschaft.
Supported by a grant from the Studienstiftung des deutschen Volkes.
§§
To whom correspondence should be addressed. Tel.: 617-732-2635;
Fax: 617-732-2593; E-mail: c.ronald.kahn@joslin.harvard.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
BAT, brown adipose
tissue;
IRS, insulin receptor substrate;
MAP kinase, mitogen-activated
protein kinase;
PAGE, polyacrylamide gel electrophoresis;
PI 3-kinase, phosphatidylinositol 3-kinase;
PKA, protein kinase A;
PKC, protein
kinase C;
UCP-1, uncoupling protein-1;
FBS, fetal bovine serum;
BSA, bovine serum albumin;
DMEM, Dulbecco's modified Eagle's medium;
PBS, phosphate-buffered saline;
PMA, phorbol 12-myristate 13-acetate.
 |
REFERENCES |
| 1.
|
Reaven, G. M.,
Lithell, H.,
and Landsberg, L.
(1996)
N. Engl. J. Med.
334,
374-381[Free Full Text]
|
| 2.
|
Karoor, V.,
Baltensperger, K.,
Paul, H.,
Czech, M. P.,
and Malbon, C. C.
(1995)
J. Biol. Chem.
270,
25305-25308[Abstract/Free Full Text]
|
| 3.
|
Issad, T.,
Combettes, M.,
and Ferre, P.
(1995)
Eur. J. Biochem.
234,
108-115[Medline]
[Order article via Infotrieve]
|
| 4.
|
Obermaier, B.,
Ermel, B.,
Kirsch, D.,
Mushack, J.,
Rattenhuber, E.,
Biemer, E.,
Machicao, F.,
and Haring, H. U.
(1987)
Diabetologia
30,
93-99[Medline]
[Order article via Infotrieve]
|
| 5.
|
Häring, H.,
Kirsch, D.,
Obermaier, B.,
Ermel, B.,
and Machicao, F.
(1986)
Biochem. J.
234,
59-66[Medline]
[Order article via Infotrieve]
|
| 6.
|
Klein, H. H.,
Matthaei, S.,
Drenkhan, M.,
Ries, W.,
and Scriba, P. C.
(1991)
Biochem. J.
274,
787-792
|
| 7.
|
Weber, T. M.,
Joost, H. G.,
Kuroda, M.,
Cushman, S. W.,
and Simpson, I. A.
(1991)
Cell. Signal.
3,
51-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Rehnmark, S.,
Nechad, M.,
Herron, D.,
Cannon, B.,
and Nedergaard, J.
(1990)
J. Biol. Chem.
265,
16464-16471[Abstract/Free Full Text]
|
| 9.
|
Puigserver, P.,
Pico, C.,
Stock, M. J.,
and Palou, A.
(1996)
Mol. Cell. Endocrinol.
117,
7-16[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Rohlfs, E. M.,
Daniel, K. W.,
Premont, R. T.,
Kozak, L. P.,
and Collins, S.
(1995)
J. Biol. Chem.
270,
10723-10732[Abstract/Free Full Text]
|
| 11.
|
Strosberg, A. D.
(1997)
J. Endocrinol.
155,
221-222[Free Full Text]
|
| 12.
|
Strosberg, A. D.
(1997)
Trends Pharmacol. Sci.
18,
449-454[Medline]
[Order article via Infotrieve]
|
| 13.
|
Lowell, B. B.,
and Flier, J. S.
(1997)
Annu. Rev. Med.
48,
307-316[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Porras, A.,
Alvarez, A. M.,
Valladares, A.,
and Benito, M.
(1998)
Mol. Endocrinol.
12,
825-834[Abstract/Free Full Text]
|
| 15.
|
Valverde, A. M.,
Lorenzo, M.,
Pons, S.,
White, M. F.,
and Benito, M.
(1998)
Mol. Endocrinol.
12,
688-697[Abstract/Free Full Text]
|
| 16.
|
Valverde, A. M.,
Lorenzo, M.,
Navarro, P.,
and Benito, M.
(1997)
Mol. Endocrinol.
11,
595-607[Abstract/Free Full Text]
|
| 17.
|
Valverde, A. M.,
Teruel, T.,
Navarro, P.,
Benito, M.,
and Lorenzo, M.
(1998)
Endocrinology
139,
1229-1238[Abstract/Free Full Text]
|
| 18.
|
Kahn, C. R.
(1997)
in
International Textbook of Diabetes Mellitus
(Alberti, K. G. M. M.
, Zimmet, P.
, DeFronzo, R. A.
, and Keen, H., eds)
, pp. 437-467, John Wiley & Sons, Ltd, Chichester, UK
|
| 19.
|
Cheatham, B.,
and Kahn, C. R.
(1995)
Endocr. Rev.
16,
117-142[Abstract/Free Full Text]
|
| 20.
|
White, M. F.,
and Kahn, C. R.
(1994)
J. Biol. Chem.
269,
1-4[Free Full Text]
|
| 21.
|
White, M. F.
(1998)
Mol. Cell. Biochem.
182,
3-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Bradford, M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Ueki, K.,
Yamamoto-Honda, R.,
Kaburagi, Y.,
Yamauchi, T.,
Tobe, K.,
Burgering, B. M.,
Coffer, P. J.,
Komuro, I.,
Akanuma, Y.,
Yazaki, Y.,
and Kadowaki, T.
(1998)
J. Biol. Chem.
273,
5315-5322[Abstract/Free Full Text]
|
| 24.
|
Sambrook, J.,
Fritch, E. F.,
and Maniatis, T.
(1990)
Molecular Cloning: A Laboratory Manual
, pp. 9.1-9.62, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 25.
|
Moyers, J. S.,
Bilan, P. J.,
Reynet, C.,
and Kahn, C. R.
(1996)
J. Biol. Chem.
271,
23111-23116[Abstract/Free Full Text]
|
| 26.
|
Sawka-Verhelle, D.,
Tartare-Deckert, S.,
White, M. F.,
and Van Obberghen, E.
(1996)
J. Biol. Chem.
271,
5980-5983[Abstract/Free Full Text]
|
| 27.
|
Inoue, G.,
Cheatham, B.,
Emkey, R.,
and Kahn, C. R.
(1998)
J. Biol. Chem.
273,
11548-11555[Abstract/Free Full Text]
|
| 28.
|
Ohsaka, Y.,
Tokumitsu, Y.,
and Nomura, Y.
(1997)
FEBS Lett.
402,
246-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Konishi, H.,
Matsuzaki, H.,
Tanaka, M.,
Ono, Y.,
Tokunaga, C.,
Kuroda, S.,
and Kikkawa, U.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7639-7643[Abstract/Free Full Text]
|
| 30.
|
Konishi, H.,
Kuroda, S.,
Tanaka, M.,
Matsuzaki, H.,
Ono, Y.,
Kameyama, K.,
Haga, T.,
and Kikkawa, U.
(1995)
Biochem. Biophys. Res. Commun.
216,
526-534[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Shimizu, Y.,
Tanishita, T.,
Minokoshi, Y.,
and Shimazu, T.
(1997)
Endocrinology
138,
248-253[Abstract/Free Full Text]
|
| 32.
|
Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
1839-1842[Free Full Text]
|
| 33.
|
Wan, Y.,
and Huang, X. Y.
(1998)
J. Biol. Chem.
273,
14533-14537[Abstract/Free Full Text]
|
| 34.
|
Vossler, M. R.,
Yao, H.,
York, R. D.,
Pan, M. G.,
Rim, C. S.,
and Stork, P. J.
(1997)
Cell
89,
73-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Kitamura, T.,
Ogawa, W.,
Sakaue, H.,
Hino, Y.,
Kuroda, S.,
Takata, M.,
Matsumoto, M.,
Maeda, T.,
Konishi, H.,
Kikkawa, U.,
and Kasuga, M.
(1998)
Mol. Cell. Biol.
18,
3708-3717[Abstract/Free Full Text]
|
| 36.
|
Shimizu, Y.,
Satoh, S.,
Yano, H.,
Minokoshi, Y.,
Cushman, S. W.,
and Shimazu, T.
(1998)
Biochem. J.
330,
397-403
|
| 37.
|
Shimizu, Y.,
Kielar, D.,
Minokoshi, Y.,
and Shimazu, T.
(1996)
Biochem. J.
314,
485-490
|
| 38.
|
Tanti, J. F.,
Gremeaux, T.,
Rochet, N.,
and Van Obberghen, E. L. M.-B. Y.
(1987)
Biochem. J.
245,
19-26[Medline]
[Order article via Infotrieve]
|
| 39.
|
Singh, H.,
and Linas, S. L.
(1997)
Am. J. Physiol.
273,
F193-F199[Abstract/Free Full Text]
|
| 40.
|
Levesque, L.,
and Crooke, S. T.
(1998)
J. Pharmacol. Exp. Ther.
287,
425-434[Abstract/Free Full Text]
|
| 41.
|
Bandyopadhyay, G.,
Standaert, M. L.,
Zhao, L., Yu, B.,
Avignon, A.,
Galloway, L.,
Karnam, P.,
Moscat, J.,
and Farese, R. V.
(1997)
J. Biol. Chem.
272,
2551-2558[Abstract/Free Full Text]
|
| 42.
|
Kotani, K.,
Ogawa, W.,
Matsumoto, M.,
Kitamura, T.,
Sakaue, H.,
Hino, Y.,
Miyake, K.,
Sano, W.,
Akimoto, K.,
Ohno, S.,
and Kasuga, M.
(1998)
Mol. Cell. Biol.
18,
6971-6982[Abstract/Free Full Text]
|
| 43.
|
Bandyopadhyay, G.,
Standaert, M. L.,
Kikkawa, U.,
Ono, Y.,
Moscat, J.,
and Farese, R. V.
(1999)
Biochem. J.
337,
461-470
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Kovsan, A. Osnis, A. Maissel, L. Mazor, T. Tarnovscki, L. Hollander, S. Ovadia, B. Meier, J. Klein, N. Bashan, et al.
Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy
Am J Physiol Endocrinol Metab,
February 1, 2009;
296(2):
E315 - E322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Emanuelli, D. Eberle, R. Suzuki, and C. R. Kahn
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance
PNAS,
March 4, 2008;
105(9):
3545 - 3550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K A. H Iwen, O. Senyaman, A. Schwartz, M. Drenckhan, B. Meier, D. Hadaschik, and J. Klein
Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes
J. Endocrinol.,
March 1, 2008;
196(3):
465 - 472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Cao, Y. Kamioka, N. Yokoi, T. Kobayashi, O. Hino, M. Onodera, N. Mochizuki, and J. Nakae
Interaction of FoxO1 and TSC2 Induces Insulin Resistance through Activation of the Mammalian Target of Rapamycin/p70 S6K Pathway
J. Biol. Chem.,
December 29, 2006;
281(52):
40242 - 40251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Miyoshi, S. C. Souza, H.-H. Zhang, K. J. Strissel, M. A. Christoffolete, J. Kovsan, A. Rudich, F. B. Kraemer, A. C. Bianco, M. S. Obin, et al.
Perilipin Promotes Hormone-sensitive Lipase-mediated Adipocyte Lipolysis via Phosphorylation-dependent and -independent Mechanisms
J. Biol. Chem.,
June 9, 2006;
281(23):
15837 - 15844.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer
Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab,
October 1, 2005;
289(4):
E586 - E590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Mulder, C. J. Tack, A. J. Olthaar, P. Smits, F. C. G. J. Sweep, and R. R. Bosch
Adrenergic receptor stimulation attenuates insulin-stimulated glucose uptake in 3T3-L1 adipocytes by inhibiting GLUT4 translocation
Am J Physiol Endocrinol Metab,
October 1, 2005;
289(4):
E627 - E633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes
J. Endocrinol.,
June 1, 2005;
185(3):
R1 - R8.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Morisco, G. Condorelli, V. Trimarco, A. Bellis, C. Marrone, G. Condorelli, J. Sadoshima, and B. Trimarco
Akt Mediates the Cross-Talk Between {beta}-Adrenergic and Insulin Receptors in Neonatal Cardiomyocytes
Circ. Res.,
February 4, 2005;
96(2):
180 - 188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Rahman, A. Dobrzyn, S.-H. Lee, P. Dobrzyn, M. Miyazaki, and J. M. Ntambi
Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue
Am J Physiol Endocrinol Metab,
February 1, 2005;
288(2):
E381 - E387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein
Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes
J. Endocrinol.,
November 1, 2004;
183(2):
299 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, Y. Cui, X. Tong, H. Ye, and S. Li
Effects of the Trp64Arg Polymorphism in the {beta}3-Adrenergic Receptor Gene on Insulin Sensitivity in Small for Gestational Age Neonates
J. Clin. Endocrinol. Metab.,
October 1, 2004;
89(10):
4981 - 4985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Entingh-Pearsall and C. R. Kahn
Differential Roles of the Insulin and Insulin-like Growth Factor-I (IGF-I) Receptors in Response to Insulin and IGF-I
J. Biol. Chem.,
September 3, 2004;
279(36):
38016 - 38024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Tseng, K. M. Kriauciunas, E. Kokkotou, and C. R. Kahn
Differential Roles of Insulin Receptor Substrates in Brown Adipocyte Differentiation
Mol. Cell. Biol.,
March 1, 2004;
24(5):
1918 - 1929.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Dubrovska, S. Verlohren, F. C. Luft, and M. Gollasch
Mechanisms of ADRF release from rat aortic adventitial adipose tissue
Am J Physiol Heart Circ Physiol,
March 1, 2004;
286(3):
H1107 - H1113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B Gonzalez-Timon, M Gonzalez-Munoz, C Zaragoza, S Lamas, and E.M Melian
Native and oxidized low density lipoproteins oppositely modulate the effects of insulin-like growth factor I on VSMC
Cardiovasc Res,
February 1, 2004;
61(2):
247 - 255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Bae, H. Cho, J. Mu, and M. J. Birnbaum
Isoform-specific Regulation of Insulin-dependent Glucose Uptake by Akt/Protein Kinase B
J. Biol. Chem.,
December 5, 2003;
278(49):
49530 - 49536.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ueki, D. A. Fruman, C. M. Yballe, M. Fasshauer, J. Klein, T. Asano, L. C. Cantley, and C. R. Kahn
Positive and Negative Roles of p85{alpha} and p85{beta} Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling
J. Biol. Chem.,
November 28, 2003;
278(48):
48453 - 48466.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sakaue, A. Nishizawa, W. Ogawa, K. Teshigawara, T. Mori, Y. Takashima, T. Noda, and M. Kasuga
Requirement for 3-Phosphoinositide-dependent Kinase-1 (PDK-1) in Insulin-induced Glucose Uptake in Immortalized Brown Adipocytes
J. Biol. Chem.,
October 3, 2003;
278(40):
38870 - 38874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L Gasparetti, C. T de Souza, M. Pereira-da-Silva, R. L G S Oliveira, M. J A Saad, E. M Carneiro, and L. A Velloso
Cold Exposure Induces Tissue-Specific Modulation of the Insulin-Signalling Pathway in Rattus Norvegicus
J. Physiol.,
October 1, 2003;
552(1):
149 - 162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, S. Eitan, J. Wu, C. J. Evans, B. Kieffer, X. Sun, and R. D. Polakiewicz
Morphine Induces Desensitization of Insulin Receptor Signaling
Mol. Cell. Biol.,
September 1, 2003;
23(17):
6255 - 6266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Entingh, C. M. Taniguchi, and C. R. Kahn
Bi-directional Regulation of Brown Fat Adipogenesis by the Insulin Receptor
J. Biol. Chem.,
August 29, 2003;
278(35):
33377 - 33383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Tseng, K. Ueki, K. M. Kriauciunas, and C. R. Kahn
Differential Roles of Insulin Receptor Substrates in the Anti-apoptotic Function of Insulin-like Growth Factor-1 and Insulin
J. Biol. Chem.,
August 23, 2002;
277(35):
31601 - 31611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Jost, M. Fasshauer, C. R. Kahn, M. Benito, M. Meyer, V. Ott, B. B. Lowell, H. H. Klein, and J. Klein
Atypical beta -adrenergic effects on insulin signaling and action in beta 3-adrenoceptor-deficient brown adipocytes
Am J Physiol Endocrinol Metab,
July 1, 2002;
283(1):
E146 - E153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Shojima, H. Sakoda, T. Ogihara, M. Fujishiro, H. Katagiri, M. Anai, Y. Onishi, H. Ono, K. Inukai, M. Abe, et al.
Humoral Regulation of Resistin Expression in 3T3-L1 and Mouse Adipose Cells
Diabetes,
June 1, 2002;
51(6):
1737 - 1744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fasshauer, J. Klein, K. M. Kriauciunas, K. Ueki, M. Benito, and C. R. Kahn
Essential Role of Insulin Receptor Substrate 1 in Differentiation of Brown Adipocytes
Mol. Cell. Biol.,
January 1, 2001;
21(1):
319 - 329.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Klein, M. Fasshauer, M. Benito, and C. R. Kahn
Insulin and the {beta}3-Adrenoceptor Differentially Regulate Uncoupling Protein-1 Expression
Mol. Endocrinol.,
June 1, 2000;
14(6):
764 - 773.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Fasshauer, J. Klein, K. Ueki, K. M. Kriauciunas, M. Benito, M. F. White, and C. R. Kahn
Essential Role of Insulin Receptor Substrate-2 in Insulin Stimulation of Glut4 Translocation and Glucose Uptake in Brown Adipocytes
J. Biol. Chem.,
August 11, 2000;
275(33):
25494 - 25501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Parpal, M. Karlsson, H. Thorn, and P. Stralfors
Cholesterol Depletion Disrupts Caveolae and Insulin Receptor Signaling for Metabolic Control via Insulin Receptor Substrate-1, but Not for Mitogen-activated Protein Kinase Control
J. Biol. Chem.,
March 23, 2001;
276(13):
9670 - 9678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Almind, L. Delahaye, T. Hansen, E. Van Obberghen, O. Pedersen, and C. R. Kahn
Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85alpha
PNAS,
February 19, 2002;
99(4):
2124 - 2128.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|